Deals channel feed – Endpoints News

Deals channel feed

As showdown with activist nears, Illumina’s CEO defends the company’s $7.1B purchase of Grail

3 years ago

Serum Institute subsidiary invests another $150M into Biocon

3 years ago

Enanta sells off over 50% of royalty payments from Mavyret in exchange for $200M

3 years ago

Novartis pays German biotech $40M for radioligand therapy, diagnostic hitting 'first-in-class' target

3 years ago

Florida-based biotech with approved cardiovascular therapy moves to go public via SPAC

3 years ago

$200M SPAC funded by billionaire Michael Dell will unwind after failing to find a partner

3 years ago

From CRL to buyout in five months: Assertio to acquire Spectrum in $248M stock deal

3 years ago

Vertex buys in on Stablix's protein stabilization approach in research and licensing deal

3 years ago

4D Molecular Therapeutics acquires eye disease asset from Fortress Biotech subsidiary

3 years ago

Lilly divests low blood sugar rescue treatment for $500M as industry focuses on dealmaking

3 years ago

A ‘blistering’ start to M&A in 2023 stokes hopes of a market rebound, as insiders predict a surge in deals

3 years ago

Moderna, IBM turn to quantum computing in hunt for new mRNA medicines

3 years ago

Bristol Myers deepens ADC pipeline in $1B+ biobuck pact with Munich startup

3 years ago

GSK will buy Bellus Health for $2B, setting up showdown with Merck

3 years ago

Danaher's takeover interest of Catalent may be on the back burner: report

3 years ago

J&J’s Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront

3 years ago

Japanese CRO buys back penny stock spinout while awaiting FDA decision on migraine candidate

3 years ago

Exclusive: Genmab's CEO touts M&A potential as it inks first partnership outside cancer

3 years ago

Updated: Merck buys Prometheus for $10.8B, bringing precision cancer chops to a potential IBD blockbuster

3 years ago

Years before $43B Pfizer deal, a mystery company made six proposals for Seagen

3 years ago

Novartis inks deal to help manufacture J&J and Legend's Carvykti

3 years ago

After raising $1.15B in just 10 weeks, Lux's Josh Wolfe shares his spending plans for his new VC fund

3 years ago

Exelixis makes counter-offer in proxy fight with hedge fund, will accept two new board members

3 years ago

Pyramid inks TROP2 pact with China biotech to follow suit of Gilead, AstraZeneca-Daiichi Sankyo

3 years ago

First page Previous page 37 38 394041 42 43 Next page Last page